As we approach the day of the release of the Interim CHF study,...

As we approach the day of the release of the Interim CHF study, interested to get insight into thoughts from others, not so much on what the result will be, as I hope nobody else knows as yet,but more on what they will tell us and what SI will tell us it means to the company.
As I am left with rather confusing view, since the last update, I felt the interim CHF data was now less of a significant indicator of go or no go on further investment of this programme that it was originally proposed last year.
So my discussion point is,
A. If the data is "positive" does it mean moving to expand the phase 111 trial and recruit another 300 more patients and further investment at what cost?
B. If it non conclusive suggest further analysis prior to committing further?
C. If it is negative put the CHF program on hold? Etc
I have tried to keep this simple and my scenarios maybe totally wrong but a given by way of example so others can provide their views in a similar way and with collective knowledge make some sense on how we think this read out will provide direction or not.